Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pharmacotherapy for personality disorders

A Hori1

  • 1Department of Psychiatry, National Center Hospital for Mental, Nervous and Muscular Disorders, Kodaira, Tokyo, Japan.

Psychiatry and Clinical Neurosciences
|July 31, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Optimisation of Radiation Therapy in Bladder Preservation Therapy for Patients With Clinical Stage T2N0M0 Bladder Cancer.

Clinical oncology (Royal College of Radiologists (Great Britain))·2022
Same author

Cost utility analysis of pharmacist counseling care for breast cancer chemotherapy outpatients.

Die Pharmazie·2019
Same author

Combating 'fake news' and social stigma after the Fukushima Daiichi Nuclear Power Plant incident-the importance of accurate longitudinal clinical data.

QJM : monthly journal of the Association of Physicians·2019
Same author

Death of the sole doctor at Takano Hospital 6 years after the Fukushima nuclear crisis-who is responsible for health care delivery in the Fukushima disaster zone?

QJM : monthly journal of the Association of Physicians·2017
Same author

Mutant botrocetin-2 inhibits von Willebrand factor-induced platelet agglutination.

Journal of thrombosis and haemostasis : JTH·2017
Same author

Structured Frameworks to Increase the Transparency of the Assessment of Benefits and Risks of Medicines: Current Status and Possible Future Directions.

Clinical pharmacology and therapeutics·2015

Pharmacotherapy effectively treats various personality disorders (PD). Low-dose antipsychotics, MAOIs, carbamazepine, lithium, and others show efficacy for specific PD symptoms and comorbidities.

Area of Science:

  • Psychiatry
  • Clinical Psychology
  • Pharmacology

Background:

  • Personality disorders (PD) encompass a range of enduring maladaptive personality traits.
  • Effective pharmacotherapy for PD remains a significant clinical challenge.
  • Evidence-based treatment guidelines for PD pharmacotherapy are crucial.

Purpose of the Study:

  • To review double-blind, placebo-controlled trials of pharmacotherapy for personality disorders.
  • To identify specific medication indications for various PD subtypes and symptoms.
  • To synthesize current evidence on psychotropic medication efficacy in PD.

Main Methods:

  • Systematic review of double-blind, placebo-controlled pharmacotherapy trials for PD.
  • Analysis of treatment responses across different PD diagnoses and symptom clusters.

Related Experiment Videos

  • Categorization of drug efficacy based on reported outcomes.

    • Main Results:

    • Low-dose antipsychotics and MAOIs benefit severe Borderline Personality Disorder (BDP) and Schizotypal Personality Disorder (SPD).
    • Carbamazepine, antipsychotics, and MAOIs help BDP with behavioral dyscontrol; lithium targets aggression; oxazepam for explosive behavior.
    • Antipsychotics aid BDP/SPD with psychotic symptoms; lithium for mood swings; adolescent PD responds to antipsychotics.

    Conclusions:

    • Specific pharmacotherapies demonstrate efficacy for distinct personality disorder presentations and comorbidities.
    • Antipsychotics, MAOIs, carbamazepine, and lithium are key agents for managing severe PD symptoms.
    • Further research is needed to optimize pharmacotherapy for diverse PD populations.